Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

C-RAD, Audiocast, Q2'25

By Inderes7/18/2025, 9:00 AM
C-Rad

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Cecilia de Leeuw
00:02 - 06:22

Welcome to our Q2 presentation, and thank you for joining us today in the middle of the Swedish summer. We have concluded a busy quarter with high activity in all markets, achieving increased order intake and securing deals despite market uncertainty. As many of you know, the foundation of our offering is the demand and need for safer cancer treatments with a focus on the patient's quality of life. And it's also about increasing efficiency in the customers' clinics. And we are on a journey. We are building an even stronger company, working hard on our financial strengths so that we can access both established and untapped markets globally with our world-leading products and services. So now let's take a look at the Q2 performance and the key takeaways. Q2 was indeed a busy quarter, and we are taking steps towards our financial targets. And I am pleased that the hard work done by the team driving marketing activities, participating in trade shows, and organizing reference site visits, which is common in the final phase of the customer buying process, is paying off. We took a number of larger deals in both the US and EMEA in the second quarter. Our order intake grew by 11% in constant currencies. The main contribution came from EMEA and the Americas, and we ended the quarter with a strong order backlog of 735 million SEK. And when looking at the backlog, approximately half of the order backlog consists of products and the other half of service contracts, which are typically 3 to 5 years. And this does, of course, provide good recurring revenue. Invoiced at the start of each quarter, revenue year on year declined by 13% in constant currencies, and the main reason is a softer order intake during 2024. And it's also worth noting that Q2 last year was boosted by approximately 20 million SEK of China deliveries due to the product registration approval, and the weaker top line had a direct impact on EBIT. And we came in with a moderate 8 million SEK. However, we have a stable gross margin, and Linda will share more soon. Our EBIT margin in the quarter was 8%. We are improving operational efficiency step by step and have reduced OpEx by 10% compared to Q2 last year. And the focus on cost efficiency is now part of our DNA, which means that we are continuously driving both cost control and implementing measures to streamline operations. And that said, we have more work to do. So let's look into the regional performance in the quarter. And I'll start off with the Americas. And our long-term focus is to strengthen our position in the US market. And we made good progress this quarter despite uncertainty in the US market. And this is mainly due to tariffs. The two large orders in the quarter that we are showing here on the slide represent different aspects of our untapped opportunity. The product order to a prominent Proton facility is for bunkers in their newly built satellite facility, and I am delighted that this existing customer decided to expand their footprint with us. The other large order is a pure service contract with a renowned cancer center on the East Coast. And this is a renewal which is important to us, and it's a clear indication of the strength of our offering and our focus on customer retention. Order intake for the Americas increased by 11% to 31 million in Q2, and revenue grew by 26% in the quarter. Moving over to EMEA, the hard work by the team is paying off in the quarter. We have good momentum, and we were rewarded with an 8.5 million SEK strategic multi-site product and services contract in France with the leading private care provider, Ronce Santé Group. And we are motivated by this, as France is a market where we are coming from a challenger position. We can also see signs of recovery in the important German market, and I am pleased that we received a 9 million SEK product and service contract from one of the most important healthcare providers in the dynamic Stuttgart region in southern Germany. Order intake increased 47% to 46 million, and revenue in EMEA was down 11% to 43 million. Still impacted by a lower order intake during last year. And finally, APAC had a softer second quarter. Q2 last year was fueled by a vital boost. Order intake benefited from the earlier Japanese market launch at the end of 2023. However, APAC is still our largest market, and there is untapped demand in advanced markets as well as the large developing markets in the region. We have a healthy market mix and see an increasing uptake of SGRT, and it's starting to become a given in the clinical workflow. Order intake declined 15% to 58 million, and revenue in APAC decreased by 34% to 44 million in Q2. And as I mentioned earlier, it's impacted by strong China deliveries last year. And if we adjust for these deliveries, APAC had a 1% growth in constant currencies. And with that, over to you, Linda. For a closer look at the financials.

Linda Frölén
06:23 - 10:32

Thank you, Cecilia. So I will take you through some of the main financials for the second quarter. As Cecilia has already explained order intake and revenue. I will not go into that again but rather focus on gross margin, cost levels, earnings, and cash flow. Gross profit for the quarter was 70 million, compared to 88 million a year ago. The decrease in gross profit follows the decrease in revenue year on year, as we had 20 million SEK in high-margin proton revenues from the long-awaited product registration approval in China last year. The gross margin for the quarter was 67% versus 68% last year, and the current levels are in line with what we have had in previous quarters and within the range of what we would have expected. The decrease in the gross margin year on year is explained by the high amount of proton revenue last year, which was partly compensated by a higher share of service revenue in this quarter. We had no proton revenues in this quarter. Looking at our main operating expenses, you see to the left of this slide that they decreased by 10% year on year, from 68 million last year to 61 million in this quarter. The decrease is mainly related to lower external expenses, as we have gradually replaced external consultants with our own employees. To the right of this slide. You see, quarter on quarter opex is up 9% from 56 million in Q1 to 61 million in this quarter. The increase is mainly related to the payout of sales commissions from earlier quarters that were not fully accounted for. The increase is also related to lower personnel expenses in Q1 due to holidays. We are monitoring our cost levels closely, and we are happy to see that our efficiency measures are showing results. Our yearly opex levels are now down by 31 million from the peak in Q3 last year, as we have now reached a more stable level. EBIT for the second quarter was 8 million compared to 18 million a year ago. The decrease in EBIT for this quarter is fully explained by the lower revenue, as both gross margin and OPEX are in line with our expectations. I can also mention that unrealized currency effects in this quarter were only minor. Our increased focus on smart spending is moving us in the right direction, and looking back a few quarters, Seerad shows continuously improved earnings and increased profitability over time. With this development as a foundation, we are well-equipped to continue to grow, as we believe we can increase the EBIT margin even more over time. According to our medium-term financial targets, we remain committed to our goals even if we may experience short-term deviations. Our cash balances decreased by 3 million during the quarter and stood at 158 million at quarter end, compared to 161 million at the beginning of the quarter. Cash flow from working capital was -8 million, which is a significant improvement from last year. But it is still on the negative side. The increase in working capital is related to accounts receivables, as a large number of old orders were invoiced late in the second quarter. A few orders on our balance sheet that have been awaiting final acceptance tests have been paid during the quarter, and many have also been invoiced after completed final acceptance tests. Some of these are expected to be paid during Q3. Last but not least, I would like to remind you that Seerad is a company with a strong balance sheet and no long-term debt. And with that, I will hand over back to Cecilia for some closing comments.

Cecilia de Leeuw
10:33 - 13:50

Thank you, Linda, and I'd like to summarize the quarter by highlighting the increased order intake generated by high market activity. In addition, I want to remind you of our financial targets for the medium term that were announced last quarter. And therefore, I'd like to conclude by taking you through our Q2 progress on our journey towards our financial targets, strategy, and priorities. So let me take you through this slide left to right. First, our strategic goal is to grow sales and expand market reach globally. Seerad already today has a global reach. And we are expanding step by step to grow our sales. And our growth target means that we will further penetrate markets, capturing unmet demand. And for Q2, order intake grew by 11% in constant currencies. And as I already mentioned, this is mainly driven by the Americas and EMEA. And this aligns with our strategic ambition to grow in the US and focus on EMEA advanced markets, where we had significant wins this quarter. Secondly, our strategic ambition is to ensure that we have world-leading products. We have a highly competitive portfolio and will continue to invest and innovate in the offering and in new complementing solutions. And in this quarter, we introduced a new and improved gating solution. And this integrated gating interface is developed together with one of our leading industry partners and integrated with the linear accelerator. And thirdly, there is truly untapped market potential. And as is the standard of care in many markets. And still, it's early days, and there are many systems without these capabilities. And hence, we see a potential to retrofit existing linear accelerators and proton machines. And we also see a great opportunity to grow services as our installed base of systems is expanding. And this is another priority for us. And services are not only important for sales and happy customers, but they also generate recurring revenue and support our profitability. And for Q2, order intake for services grew by 86% in constant currencies compared to Q2 last year. And finally, we are steering towards our financial targets. And our company has good financial stability and is building a resilient organization, supporting scalability. And it's resilient from a market perspective, building a more mature company that supports growth. And for Q2, we have further trimmed down our OpEx by 10%. And this is mainly achieved by replacing consultants, as you heard from Linda. Within administration and also within service. And we are taking steps towards our financial targets. And with that, over to you, Moderator for Q&A.

Operator
13:54 - 14:18

If you wish to ask a question, please dial the Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key on your telephone keypad. If you are listening to the presentation through the webcast, you can ask a question by clicking the raised hand symbol. The next question comes from Oscar Bergman from Redeye. Please go ahead.

Oscar Bergman
14:21 - 14:48

Hello, Cecilia and Linda. I have a few questions that are not really related to the quarter, but more so on the general level. Uh, the first one is about competition for service scanning. Could you just briefly elaborate on the main value propositions? And also, are your selling activities dependent on any cyclical buying patterns among your customers?

Cecilia de Leeuw
14:51 - 16:15

So, if I start this off. So, uh, when it comes to the value proposition, it's, um, both in terms of targeting only the healthy tissue on the patient, which has societal value, and also, of course, patient value. Uh, the other point is, of course, the efficiencies in the clinic. And this is a very minor investment for the clinic. So, we say it's typically only about 5% of the total investment. So for a lot of return, it's a minor investment. And, in terms of how these cycles work, this is not typically a cycle as such. Uh, but it's something that we see happening over the years. Uh, we sometimes see higher purchases at the end of the year, depending on the budgets for the hospital. But that, uh, that depends. And, you know, it's also worth saying that this is a highly regulated market. So, when it comes to competition, it's not such an easy market to enter because you have to have registration in each and every market.

Oscar Bergman
16:17 - 16:22

Sure. And how do you typically compete? Do you compete on pricing, or is it more on functionality?

Cecilia de Leeuw
16:24 - 16:42

Uh, I would say that we always try to compete on functionality and can probably say that we have a lot of uniqueness here. Uh, however, it is also true that sometimes there is a market price that we have to manage. So I would say it's a combination.

Oscar Bergman
16:44 - 17:00

So, so if I, if I start, uh, start this off. And if you look at the market, can you see any estimates on what percentages of the machines are equipped with this type of technology and how you expect this to change in the coming five years? If there are any big trends, they are moving this in the right direction.

Cecilia de Leeuw
17:01 - 17:50

And, as I mentioned earlier in the presentation, we see that it's increasingly becoming the standard of care. Uh, and in advanced markets, let's say Germany, for example, there is a slightly higher percentage compared to developing markets. You have markets that so far don't have any STDs. So, so it's, uh, it's a big difference. Uh, but the standards that came out at the end of 2022, of course, are supportive. Uh, so, uh, but if we look at the attachment rate in different markets, uh, in the US, for example, it's slightly higher, it's more, uh, north of 40%, and in developing markets, it could be, you know, from zero and up.

Oscar Bergman
17:51 - 17:59

So, so if I, if I start, uh, start this off. And I guess it's fair to assume that for the proton centers, you have an even higher attachment rate than for photon.

Cecilia de Leeuw
18:01 - 18:37

It varies there as well. There are a lot of opportunities. And if you look at the opportunity, sometimes it's part of a newly built bunker. Sometimes we retrofit existing proton machines. But also there, as an example, we have a client at the Miami Cancer Center in Florida, USA. And there, they have CBCT on all machines, both proton and photon. So that's, of course, a very strong reference for us.

Oscar Bergman
18:38 - 18:52

It's a lot of opportunities. It's a lot of opportunities. And just one final question from me. Maybe this is mentioned somewhere in the report or on your web page. But, uh, can you, uh, say how many art centers worldwide you are actually installed at today?

Cecilia de Leeuw
18:54 - 19:02

We don't typically disclose that today, but we are in more than 50 countries worldwide.

Oscar Bergman
19:03 - 19:07

It's a lot of opportunities. But are you looking into providing such details going forward?

Cecilia de Leeuw
19:08 - 19:09

Yeah, we'll look into that.

Oscar Bergman
19:11 - 19:12

It's a lot of opportunities. Thank you.

Cecilia de Leeuw
19:13 - 19:13

It's a lot of opportunities.

Operator
19:18 - 19:23

The next question comes from Christian Lee from Pareto Securities. Please go ahead.

Christian Lee
19:26 - 19:49

It's a lot of opportunities. And good morning, Linda. Thank you for taking my questions. I have three, please. Uh, the first is regarding the strong order intake in the quarter. Um, do you expect the good momentum in EMEA to continue in the second half of the year? And how do you view your chances of winning more significant product orders in the US in the near term? It's a lot of opportunities.

Cecilia de Leeuw
19:52 - 20:17

So when it comes to EMEA, as I mentioned earlier, it's nice to see that EMEA is starting to pick up again. Uh, of course, it's too early to say. And I.

Christian Lee
20:17 - 20:17

Think.

Cecilia de Leeuw
20:17 - 20:18

You can.

Christian Lee
20:18 - 20:18

Yes.

Cecilia de Leeuw
20:18 - 20:20

Can you repeat the US question?

Christian Lee
20:22 - 20:27

Yes. What are your chances of winning more significant product orders in the US?

Cecilia de Leeuw
20:38 - 20:41

Yes. You have to take it one more time, Christiane. Sorry.

Christian Lee
20:43 - 20:58

Yes. Sorry about the bad line here. Um, I was wondering if you could share your view on your chances of winning more significant product orders in the US in the near term, as the majority have been service contracts.

Cecilia de Leeuw
20:59 - 21:52

Right. Uh, no, that's, uh, it's, it's, uh, it's, um, you know, to start off, you know, we are also very happy with the, uh, the Texas order, of course, which is a, you know, pure product order. Uh, but, um, uh, we see a strong opportunity in the US to, uh, as I've talked about before, retrofit also existing LINACs. Uh, but we also see indications that customers are able to make faster decisions on OpEx investments than on CapEx products. Uh, and it has been favorable for our service business. Uh, but in the short term, it might impact our product business. And our assessment is that this is connected to the uncertainty around trade and tariffs.

Christian Lee
21:55 - 22:03

And I. And I. And I. And my second question, did you have any negative impact on the results from the tariff situation?

Linda Frölén
22:05 - 22:07

Uh, not in this quarter, no.

Christian Lee
22:10 - 22:14

Do you expect any negative impact in the third quarter?

Linda Frölén
22:16 - 22:45

Uh, as you all know, these decisions are put on hold for now. Uh, our current assessment is that it's only the hardware that will be affected. And our general terms and conditions allow us to pass on the cost of tariffs to the customer. And, uh, in the near term, we don't see any major effects of the tariffs.

Christian Lee
22:47 - 23:01

Okay. That's clear. Thank you very much. And my last question, given that organic sales decreased by 13% in the second quarter, do you feel confident about reaching your target of 10% growth for the full year?

Cecilia de Leeuw
23:03 - 23:29

So just to remind you of our financial targets, it's actually over the mid-term. Uh, so it's in the mid-term, uh, so we will continue working and, uh, looking at the order intake, uh, which is the first important step to get revenue. Uh, and just as a reminder, it's typically 6 to 8 months from order to delivery. That's a good step in the right direction.

Christian Lee
23:33 - 23:35

Okay. Perfect. Thank you very much.

Operator
23:41 - 24:01

As a reminder, if you wish to ask a question, please dial the Pound Key on your telephone keypad or click the raised hand symbol on the webcast. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Cecilia de Leeuw
24:11 - 24:35

Thank you all for attending our Q2 presentation. And I mentioned earlier that we are on a journey, and this is vital because we are here to increase safety and efficiency in cancer care. And this is important not only for patients and clinics, but also for shareholders. And with that, I want to thank you and wish you a nice summer.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…